X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (529) 529
Conference Proceeding (347) 347
Publication (68) 68
Book Review (2) 2
Paper (2) 2
Patent (2) 2
Reference (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
hematology (354) 354
oncology (314) 314
humans (286) 286
index medicus (211) 211
rituximab (114) 114
male (103) 103
female (101) 101
aged (96) 96
middle aged (94) 94
antineoplastic combined chemotherapy protocols - therapeutic use (83) 83
treatment outcome (82) 82
lymphomas (79) 79
mantle cell lymphoma (77) 77
adult (73) 73
non-hodgkins-lymphoma (71) 71
prognosis (66) 66
chemotherapy (59) 59
cancer (54) 54
neoplasm staging (53) 53
transplantation (52) 52
lymphoma (51) 51
lymphoma, mantle-cell - drug therapy (50) 50
follow-up studies (49) 49
survival (47) 47
therapy (47) 47
follicular lymphoma (45) 45
aged, 80 and over (44) 44
antineoplastic agents - therapeutic use (44) 44
chronic lymphocytic-leukemia (44) 44
lymphoma, mantle-cell - therapy (44) 44
progression-free survival (43) 43
lymphoma, mantle-cell - pathology (41) 41
care and treatment (39) 39
survival analysis (37) 37
trial (37) 37
cyclophosphamide (36) 36
recurrence (36) 36
antibodies, monoclonal - therapeutic use (33) 33
combined modality therapy (31) 31
lymphoma, mantle-cell - mortality (31) 31
b-cell lymphoma (30) 30
immunochemotherapy (30) 30
prospective randomized-trial (30) 30
lymphoma, follicular - drug therapy (29) 29
high-dose therapy (28) 28
immunotherapy (28) 28
disease-free survival (27) 27
lymphoma, mantle-cell - genetics (27) 27
medicine, general & internal (27) 27
drug therapy (26) 26
lymphoma, mantle-cell - diagnosis (26) 26
stem-cell transplantation (26) 26
hemic and lymphatic diseases (25) 25
expression (24) 24
abridged index medicus (23) 23
antibodies, monoclonal, murine-derived (23) 23
clinical trials (23) 23
cyclophosphamide - administration & dosage (23) 23
1st-line treatment (22) 22
bortezomib (22) 22
elderly-patients (22) 22
europe - epidemiology (22) 22
lymphoma, follicular - pathology (22) 22
radioimmunotherapy (22) 22
randomized controlled trials as topic (22) 22
randomized controlled-trial (22) 22
remission induction (22) 22
research (22) 22
leukemia (21) 21
patients (21) 21
phase-ii (21) 21
analysis (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (20) 20
incidence (20) 20
international prognostic index (20) 20
medicine & public health (20) 20
risk assessment (20) 20
risk factors (20) 20
lymphocytes b (19) 19
non-hodgkin-lymphoma (19) 19
hematopoietic stem cell transplantation (18) 18
indolent lymphoma (18) 18
life sciences (18) 18
lymphoma, follicular - mortality (18) 18
lymphoma, follicular - therapy (18) 18
open-label (18) 18
anti-cd20 monoclonal-antibody (17) 17
antineoplastic agents - administration & dosage (17) 17
antineoplastic agents - adverse effects (17) 17
bone-marrow-transplantation (17) 17
clinical trials as topic (17) 17
minimal residual disease (17) 17
plus rituximab (17) 17
transplantation, autologous (17) 17
vincristine - administration & dosage (17) 17
antibodies, monoclonal, murine-derived - administration & dosage (16) 16
antineoplastic agents (16) 16
combination (16) 16
doxorubicin - administration & dosage (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMBINATION | FLUDARABINE | STUDY-GROUP GLSG | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1111 - 1122
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 7, pp. 730 - 737
Journal Article
by Gröbner, Susanne N and Worst, Barbara C and Weischenfeldt, Joachim and Buchhalter, Ivo and Kleinheinz, Kortine and Rudneva, Vasilisa A and Johann, Pascal D and Balasubramanian, Gnana Prakash and Segura-Wang, Maia and Brabetz, Sebastian and Bender, Sebastian and Hutter, Barbara and Sturm, Dominik and Pfaff, Elke and Hübschmann, Daniel and Zipprich, Gideon and Heinold, Michael and Eils, Jürgen and Lawerenz, Christian and Erkek, Serap and Lambo, Sander and Waszak, Sebastian and Blattmann, Claudia and Borkhardt, Arndt and Kuhlen, Michaela and Eggert, Angelika and Fulda, Simone and Gessler, Manfred and Wegert, Jenny and Kappler, Roland and Baumhoer, Daniel and Burdach, Stefan and Kirschner-Schwabe, Renate and Kontny, Udo and Kulozik, Andreas E and Lohmann, Dietmar and Hettmer, Simone and Eckert, Cornelia and Bielack, Stefan and Nathrath, Michaela and Niemeyer, Charlotte and Richter, Günther H and Schulte, Johannes and Siebert, Reiner and Westermann, Frank and Molenaar, Jan J and Vassal, Gilles and Witt, Hendrik and Zapatka, Marc and Burkhardt, Birgit and Kratz, Christian P and Witt, Olaf and Tilburg, Cornelis M. Van and Kramm, Christof M and Fleischhack, Gudrun and Dirksen, Uta and Rutkowski, Stefan and Frühwald, Michael and Hoff, Katja Von and Wolf, Stephan and Klingebiel, Thomas and Koscielniak, Ewa and Landgraf, Pablo and Koster, Jan and Resnick, Adam C and Zhang, Jinghui and Liu, Yanling and Zhou, Xin and Waanders, Angela J and Zwijnenburg, Danny A and Raman, Pichai and Brors, Benedikt and Weber, Ursula D and Northcott, Paul A and Pajtler, Kristian W and Kool, Marcel and Piro, Rosario M and Korbel, Jan O and Schlesner, Matthias and Eils, Roland and Jones, David T. W and Lichter, Peter and Chavez, Lukas and Pfister, Stefan M and ICGC PedBrain-Seq Project ICGC and ICGC MMML-Seq Project and ICGC PedBrain-Seq Project
Nature, ISSN 0028-0836, 03/2018, Volume 555, Issue 7696, pp. 321 - 327
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 03/2019, Volume 10, Issue 1, pp. 1459 - 19
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10020, pp. 770 - 778
Journal Article
by Horwitz, Steven and O'Connor, Owen A and O'Connor, Owen and Pro, Barbara and Illidge, Tim and Fanale, Michelle and Advani, Ranjana and Bartlett, Nancy and Bartlett, Nancy L and Christensen, Jacob Haaber and Morschhauser, Franck and Domingo-Domenech, Eva and Rossi, Giuseppe and Kim, Won Seog and Feldman, Tatyana and Lennard, Anne and Belada, David and Illés, Árpád and Tobinai, Kensei and Tsukasaki, Kunihiro and Yeh, Su-Peng and Shustov, Andrei and Hüttmann, Andreas and Savage, Kerry and Savage, Kerry J and Yuen, Sam and Iyer, Swaminathan and Zinzani, Pier Luigi and Hua, Zhaowei and Little, Meredith and Rao, Shangbang and Woolery, Joseph and Manley, Thomas and Trümper, Lorenz and Aboulafia, David and Alpdogan, Onder and Ando, Kiyoshi and Arcaini, Luca and Baldini, Luca and Bellam, Naresh and Yehuda, Dina Ben and Benedetti, Fabio and Borchman, Peter and Bordessoule, Dominique and Brice, Pauline and Briones, Javier and Caballero, Dolores and Carella, Angelo Michele and Chang, Hung and Cheong, June Weon and Cho, Seok-Goo and Choi, Ilseung and Choquet, Sylvain and Colita, Andrei and Congui, Angela Giovanna and D'amore, Francesco and Dang, Nam and Davison, Kelly and de Guibert, Sophie and Brown, Peter de Nully and Delwail, Vincent and Demeter, Judit and di Raimondo, Francesco and Do, Young Rok and Domingo, Eva and Douvas, Michael and Dreyling, Martin and Ernst, Thomas and Fay, Keith and Ferrero, Silvia Fernandez and Flinn, Ian Winchester and Forero-Torres, Andres and Fox, Christopher and Friedberg, Jonathan and Fukuhara, Noriko and Garcia-Marco, Jose and Cruz, Jorge Gayoso and Codina, Jose Gomez and Gressin, Remy and Grigg, Andrew and Gurion, Ronit and Haioun, Corinne and Hajek, Roman and Hanel, Mathias and Hatake, Kiyohiko and Hensen, Robert and Horowitz, Netanel and Huttmann, Andreas and Illes, Arpad and Ishizawa, Kenichi and Islas-Ohlmayer, Miguel and Jacobsen, Eric and Janakiram, Murali and Jurczak, Wojciech and Kaminski, Mark and Kato, Koji and Kirgner, Ilya and Kuo, Ching-Yuan and Lazaroiu, Mihaela Cornelia and Du, Katell Le and ... and ECHELON 2 Study Grp and ECHELON-2 Study Group
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10168, pp. 229 - 240
Journal Article